Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561978 | 1.00 | CSNK2A2 (0.31) | CSNK2A2CSNK2A1 | |
| SCHEMBL561977 | 1.00 | CSNK2A2 (0.31) | CSNK2A2CSNK2A1 | |
| SCHEMBL17076623 | 0.84 | ALOX5 (0.35) | CSNK2A2CSNK2A1 | |
| SCHEMBL16338060 | 0.77 | ALOX5 (0.33) | CSNK2A2CSNK2A1 | |
| SCHEMBL16338061 | 0.77 | ALOX5 (0.33) | CSNK2A2CSNK2A1 | |
| SCHEMBL1711675 | 0.77 | CPN1 (0.35) | CSNK2A2CSNK2A1 | |
| SCHEMBL28722096 | 0.75 | CSNK2A2 (0.37) | CSNK2A2CSNK2A1 | |
| SCHEMBL3630902 | 0.74 | LMNA (0.32) | CSNK2A2CSNK2A1 | |
| Hydrochloric Acid SCHEMBL31255580 | 0.73 | LMNA (0.32) | CSNK2A2CSNK2A1 | |
| SCHEMBL28722121 | 0.72 | CSNK2A2 (0.35) | CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642633-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130137733-A1 | Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2012-02-09 | — | — | US | disclosed |
| US-8013003-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | GRIN2A, GRIN2B, SLC18A2 | CSNK2A2 3554/4885CSNK2A1 3854/4885 |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | DRD2, DRD3, GAP43 | CSNK2A2 3687/4885CSNK2A1 3693/4885 |
| US-20130137733-A1 | Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses | DRD2, DRD3, GAP43 | CSNK2A2 3687/4885CSNK2A1 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.